DOCSLIB.ORG

NEOHEART 2020 5Th INTERNATIONAL CONFERENCE Cardiovascular Management of the Neonate OCTOBER 27-30, 2020 ADVANCE PROGRAM

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NEOHEART 2020 5Th INTERNATIONAL CONFERENCE Cardiovascular Management of the Neonate OCTOBER 27-30, 2020 ADVANCE PROGRAM A Global Virtual Event NEOHEART 2020 5th INTERNATIONAL CONFERENCE Cardiovascular management of the neonate OCTOBER 27-30, 2020 ADVANCE PROGRAM #neoheart2020 neoheartsociety.org NEOHEART 2 0 2 0 GOES VIRTUAL We hope you and your family are safe and healthy during this difficult time. In the wake of the COVID-19 pandemic, we have paused how we traditionally host medical conferences. Our team has reimagined NeoHeart 2020 as an immersive, transformative virtual experience. The possibilities are endless. For the very first time in NeoHeart's history, we will be hosting our conference virtually. Join us as we take a step into the future. Log in and connect with a global audience. NEOHEART 2020 Cardiovascular Management of the Neonate a global virtual event October 27-30, 2020 Our promise: To deliver stimulating & insightful sessions, lively and engaging discussions, guaranteed to capture your attention. Meet hundreds of your peers from around the world. Engage with more than 100 leading experts in the field. Collaborate, Seek solutions, Share ideas, & Participate. Join the Conversation. This October. register at neoheartsociety.org NEOHEART 2020 A MESSAGE FROM THE A GLOBAL NEONATAL HEART SOCIETY VIRTUAL EVENT We hope you and your family are well. OCT.27-30, 2020 The Neonatal Heart Society in partnership with Columbia University and New York Presbyterian's Morgan Stanley Children's Hospital, is proud to host NeoHeart 2020. Our hope was to host NeoHeart in Manhattan in New York City as a live- in-person event. Due to the pandemic, the Society and its partners have re- imagined the conference as a global virtual event. Other aspects of NeoHeart have not changed. NeoHeart remains a conference like no other. At NeoHeart, we disrupt silos and build bridges so that we can learn from each other. At NeoHeart, you share ideas. You question norms. You challenge dogma. Ganga Krishnamurthy MBBS And you find common ground with an expert in another President, Neonatal Heart Society field. You hear what new idea is pushing the field forward. What novel therapy is emerging on the horizon. Most importantly, you have ready access to experts from many specialities. Help build a world where This is what makes a truly fulfilling and successful every newborn infant conference. with cardiopulmonary disease receives optimal NeoHeart provides a venue for this experience. care for a healthier future Whether through workshops or critical thinking during case and panel discussions, each attendee will be pushed to think outside the box. Attendees will walk away with new ideas, tools and the potential to be part of a a leading-edge team at their Center. Join us in the virtual world! What NeoHeart is about NeoHeart is the flagship annual conference of the Neonatal Heart Society. We bring together clinicians, leading experts, thought leaders and researchers across the global scientific community to exchange new knowledge & share the latest research on neonatal cardiopulmonary disorders. Why you should attend NeoHeart 2020? the latest in science & cutting-edge research Learn new ideas and tools Expand yout network meet a global audience Experience a virtual conference- content you want, when you want Exchange ideas Gain insight from over 100 experts Who attends NeoHeart NeoHeart? by the numbers 538 Attendees at NeoHeart 2019 Neonatologists, pediatric cardiologists, cardiac surgeons, pediatric cardiac intensivists, pediatric intensivists, anesthesiologists, basic scientists, nurses, 15 advancedpractice providers, perfusionists, pharmacists, nutritionists, sonographers, Countries at NeoHeart 2019 respiratory therapists, Residents, Fellows and many more! The NeoHeart Experience: The only international conference dedicated to neonates with cardio-pulmonary disease NEOHEART 2020 CONFERENCE SCIENTIFIC ORGANIZING COMMITTEE Objectives Formulate an evidence based approach for optimal treatment of neonatal cardiopulmonary disorders including latest therapies. Know recent advances in the management of neonates with Hypoplastic left heart syndrome. Know novel therapeutic options available for the Ganga Krishnamurthy MBBS closure of a hemodynamically significant PDA in President, Neonatal Heart Society preterm infants including with percutaneous Associate Professor of Pediatrics transcatheter interventions. Medical Director, Infant Cardiac Unit Know how to manage term and preterm New York-Presbyterian Morgan Stanley neonates with persistent pulmonary hypertension Children's Hospital Columbia University Irving Medical Center, physiology or pulmonary hypertension secondary New York to BPD. Know how to monitor for development of pulmonary vein stenosis in preterm infants and therapeutic options available. Formulate an evidence based approach to diagnosis, monitoring and management of neonatal circulation and shock states. Describe the up-to-date basic science behind cardiopulmonary disorders. Emile Bacha MD Know the latest in neonatal resuscitation Chief, Division of Cardiac, Thoracic science. and Vascular Surgery New York-Presbyterian/ Know the latest advances and future Columbia University Medical Center, New York perspectives on Neonatal ECMO. Know current outcomes of preterm neonates with congenital heart disease and treatment options including non-surgical interventions. Know how to formulate an evidence based approach to providing optimal nutrition and developmentally appropriate care to preterm infants with congenital heart disease. Know modifiable and non-modifiable factors that influence neurodevelopmental outcomes in Richard A Polin MD infants with congenital heart disease. Professor & Executive Vice Chair, Department of Pediatrics New York-Presbyterian/ Columbia University Medical Center, New York NEO HEART 2 0 2WORKSHOPS 0 & MASTERCLASSES NeoHeart 2020 I Oct 27-30, 2020 I a global virtual event I COPYRIGHT NEONATAL HEART SOCIETY NeoHeart 2020 I Oct 27-30, 2020 I a global virtual event I COPYRIGHT NEONATAL HEART SOCIETY 12:30 PM US EST- 2:30 PM US EST 12:30 PM US EST- 2:30 PM US EST 12:30 PM US EST- 2:30 PM US EST NeoHeart 2020 I Oct 27-30, 2020 I a global virtual event I COPYRIGHT NEONATAL HEART SOCIETY NEOHEART 2020 KEYNOTE SPEECH KEYNOTE SPEAKER: RICHARD A JONAS MD The Neonatal Heart Society recognizes Dr Richard A Jonas for his extraordinary accomplishments and legendary career as a pediatric cardio-thoracic surgeon. Dr. Jonas is the Chief of Cardiac Surgery and the Co-Director of the Children's National Heart Institute at the Children's National Health System, Washington, DC. Richard A Jonas MD Reflections on a career in congenital cardiac surgery OCTOBER 27, 2020, 3:00- 3:30 PM US EST ABOUT RICHARD JONAS KEYNOTE SPEAKER: RICHARD A JONAS MD OCTOBER 27, 2020, 3:00- 3:30 PM US EST Dr. Jonas joined the staff of Children's National Medical Center in 2004 as the Chief of Cardiovascular Surgery, Co-Director of the Children's Heart Institute and Cohen Funger Professor of Cardiac Surgery. He undertook his general surgical training at the Royal Melbourne Hospital in Melbourne Australia and subsequently his cardiothoracic surgical training at Royal Children's Hospital in Melbourne and Green Lane Hospital in Auckland New Zealand. After fellowships at the Brigham and Women's Hospital and Children's Hospital Boston he was appointed to the Department of Surgery at Harvard Medical School in 1984. In 1994 Dr. Jonas was appointed to the William E Ladd Chair of Surgery at Harvard Medical School and became the Cardiovascular Surgeon in Chief at Children's Hospital Boston. Dr. Jonas has an active clinical practice in congenital cardiac surgery. He also maintains his own NIH supported laboratory research program in addition to his administrative responsibilities. He is the author of over 400 peer-reviewed publications and 2 textbooks. In addition to his responsibilities at Children’s Hospital Dr Jonas is a consultant to the FDA and has participated in numerous study sections of the NIH. He has worked with Project Hope for more than 25 years in establishing pediatric heart surgery in Shanghai, China as well as helping with the design and development of the Shanghai Children’s Medical Center. In 2005/6 Dr Jonas was the President of the American Association for Thoracic Surgery and in 2009/10 was President of the Congenital Heart Surgeon’s Society of North America. He was President of the World Society for Pediatric and Congenital Heart Surgery from 2016-2018. NEOHEART 2020 KEYNOTE SPEECH KEYNOTE SPEAKER: OLA DIDRIK SAUGSTAD MD, PHD The Neonatal Heart Society recognizes Dr Saugstad for his extraordinary accomplishments and legendary career as a neonatologist and a physician scientist. Dr. Saugstad is a Professor of Pediatrics at the University of Oslo, Norway. Fighting for Air How pure oxygen to term infants was abandoned in the delivery room OCTOBER 29, 2020, 3:00- 3:30 PM US EST ABOUT OLA DIDRIK SAUGSTAD MD, PHD KEYNOTE SPEAKER: OLA DIDRIK SAUGSTAD MD, PHD OCTOBER 29, 2020, 3:00- 3:30 PM US EST Dr Saugstad is a Professor in Pediatrics and served as the Director & Head of the Department of Pediatric Research at the University of Oslo and Oslo University Hospital from 1991 to 2017. He served as a Consultant in Neonatology at Oslo University Hospital, Rikshospitalet from 1986 to 2017. Since 2018, Dr Saugstad serves as an adjunct Professor at the Ann and Robert H Lurie Children’s Hospital of Chicago in the Northwestern University Feinberg School of Medicine. Dr Saugstad received his MD, PhD degrees from the University of Oslo, completed residency in Pediatrics in 1984 at the Oslo University Hospital where he also started his career as a neonatologist. Dr Saugstad was a research Fellow at the University of Uppsala (1973-74), and the Fogarty Fellow at the University of California, San Diego (1980-81) and a Visiting Research Associate at the University of California San Francisco (1986). During his career, he also served as the Head of the Norwegian Newborn Screening Program and served as the Head of the Department of Women and Child Health. Dr Saugstad has 505 publications recorded in PubMed, with more than 12 000 citations (web of knowledge). H index: (Web of Knowledge) 56, (Google scholar) 77.
Load more

Recommended publications
  • Internal Medicine – Focus on Pediatrics/Neonatology Learning Experience 1 & 2
    CONTROLLED UNLESS PRINTED PGY1 – Internal Medicine – Focus on Pediatrics/Neonatology Learning Experience 1 & 2 Preceptors* Emily Siegrist, PharmD ([email protected]) Deanna Dickson, PharmD ([email protected]) Elaine Rietmann, PharmD ([email protected]) Hours: 0700 to 1730 *Primary preceptors and preceptors will be assigned dependent on pharmacist schedule during rotation General Description This rotation is concentrated in four weeks of exposure to the pediatric and neonatal populations at Asante Rogue Regional Medical Center. The clinical pharmacist on the team is responsible for ensuring safe and effective medication use for all patients admitted to the pediatric and neonatal intensive care unit. Routine responsibilities include: review and confirmation of appropriateness of medication for the patient population based upon age, weight, indication and pharmacokinetic considerations; completion of consults and medication therapy protocols in areas including dosing and monitoring of TPN, kinetics, evaluation of anti-infectives, addressing formal consults for non-formulary drug requests and providing patient and family education. The pharmacist also provides drug information and education to healthcare professionals as requested. Expectations of the Resident Residents will attend NICU and Pediatric rounds every day. During this rotation the resident will focus on caring for patients in the pediatric and neonatal intensive care units. Residents will actively seek to identify the potential for significant medication-related
    [Show full text]
  • Study Guide Medical Terminology by Thea Liza Batan About the Author
    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
    [Show full text]
  • OTITIS MEDIA (OM): a COMMON COMPLICATION OFNASOTRACH- AMNIOTIC Nuid - DIAGNOSIS USING B2 MICROGLOBULIN
    NEONATOLOGY TUBULAR DYSFUNCTION IN INFANTS WITH MECONIUM STAINED OTITIS MEDIA (OM): A COMMON COMPLICATION OFNASOTRACH- AMNIOTIC nUID - DIAGNOSIS USING B2 MICROGLOBULIN. EAL INTUBATION (NTI) IN THE NEONATE. Janet Purn, Ilana t 1469 Ronald J.Portman, Jennifer W.Cole, Jeffrey M.Perlman, 1472 Zarafu, (Spon. Franklin C. Behrle) Univ. of Medicine Yin Lim, Alan M.Robson, Washington Univ. Sch. of Med., St.Louis and Dentistry: New Jersey Medical School, Newark Beth Israel Med- Children's Hospital, Department of Pediatrics, St.Louis, MO ical Center (NBIMC) Dept. of Peds., Newark, N. J. 07112 Urinary concentrations of B2 microglobulin (B2M) and creatin- Auditory Brainstem Responses (ABR) are recorded in the Newborn ine were measured in normal term infants and in those born with Special Care Center at NBIMC prior to discharge.From 9/82 to 8/83 meconium stained amniotic fluid (MEC). None of the infants or 252 infants (INFS) had ABR evaluations. One hundred one INFS were their mothers had conditions known to modify B2M excretion. Apgar ventilated through endotracheal tube. They were assessed by ABR scores for the normal and MEC infants averaged 8.8 and 7.7 re- and otoscopy~ta mean postnatal age of 39 days (D). The mean spectively at 1 min and 9.0 and 8.2 at 5 min. Urinary B2M to cre- birthweight (BW) of intubated INFS was 1895gms (580-4170), and mean atinine levels (mglgm) increased significantly (~<.01)in the duration of intubation was 5.8 D. NTI was used in 98 INFS,oral in- normal infants from day 1 (1.5+1.3:n=29) to day 3 (3.5+2.B:n=21) tubation in 3 and 18 had NTI and oral tubes.
    [Show full text]
  • Eric D. Schultz, DO, MPH
    Eric D. Schultz, DO, MPH EDUCATION 07/2005-06/2008 Duke University Medical Center Durham, NC Neonatal-Perinatal Intensive Care Fellowship 07/2002-06/2005 University of California, Irvine Orange, CA Pediatric Residency 08/1998-06/2002 Western University of Health Sciences Pomona, CA D.O. 08/1993-05/1996 California State University, San Diego San Diego, CA M.P.H.: Epidemiology 09/1988-06/1993 University of California, San Diego La Jolla, CA B.A.: Chemistry/Biochemistry PROFESSIONAL EXPERIENCE 03/2011 – Present Texas A & M College of Medicine Round Rock, TX Clinical Assistant Professor: Dept. of Pediatrics 09/2010 – Present Greater Austin Allergy, Asthma & Immunology Austin, TX Allergy, Asthma and Immunology Physician 09/2010 – 09/2016 Sneeze Allergy, Cough and Sinus Centers Austin, TX Chief Medical Officer AN EXPERT APPROACH TO ALLERGY RELIEFSM • AUSTINALLERGIST.COM 06/2010 – 09/2010 Pediatric Subspecialty Faculty Orange, CA Associate Director of Neonatal-Perinatal Education 04/2010 – 09/2010 University of California, Irvine Orange, CA Clinical Instructor: Division of Neonatology 06/2009 – 09/2010 Children’s Hospital of Orange County Orange, CA Neonatologist 07/2008 – 06/2009 Rady Children’s Hospital of San Diego San Diego, CA Neonatologist 07/2008 – 06/2009 Sharp Mary Birch Hospital San Diego, CA Neonatologist 10/2006 – 06/2008 Columbus Regional Hospital Whiteville, NC Pediatric Hospitalist GRANTS Duke University Medical Center Children’s Miracle Network Grant T32 NIH National Research Service Award AN EXPERT APPROACH TO ALLERGY RELIEFSM • AUSTINALLERGIST.COM CLINICAL TRIALS 2006-2008 Principal Investigator: Duke University. Children’s Miracle Network Grant. Blocking mast cell homing prevents airways hyperreactivity in hyperoxia exposed newborn rats.
    [Show full text]
  • Effects of Severe Hypoxia on Dilator Prostaglandin Synthesis
    NEONATOLOGY 325A MYOINOSITOL SUPPLEMENTATION IN RESPIRATORY DISTRESS THROMBOXANE B LEVEL S IN NEONATES WITH PERSISTENT SYNDROME (RDS). Mikko Hallman, Anna-Liisa FETAL CIRCULAfiON. Cathy Harrunerman, Elene Strates, Pat Bromberger. Childrens' Hosp ital, Univ. Helsinki, Stuart Berger and W1lliam Za1a. (Spon . by K.S. Lee), Fi nland; Univ. California, San Diego, CA . University of Chicago Medical Center, Department of Pedi atrics, Myoinositol (INO) may potentiate hormone-induced lung matura­ Chicago, IL. tion & increase surfactant in lung damage (Ped Re • 17 , 378A,-83; Plasma levels of Thromboxane B2 (TxB 2) were determined by Life Sci 31, 175,-82). Serum INO is high in RDS at birth. INO de­ radioimmunoassay in seven infants with persistent fetal circu la­ creases after bi rth , in part because the diet may contain only tion (PFC) of various etiologies. The levels were found to be little INO. In the present randomized double-blind trial involv­ quite elevated as compared with those of seven neonates with ing 22 RDS cases (BW <2000g), we studied the effect of INO on other cardiorespi ratory problems, but without PFC: serum INO and on lung phospholipids . Either INO or glucose (GLU) MEAN (dose: 1 ml isotonic sugar/kg q 6 h) was given orally for 7 days, PFC 2426 12 2540 585 591 628 331 1016.!:_1025 beginning da y two. The amount of INO was similar to. INO in 200 ml/kg of preterm breast milk. There was no d1fferences 1n Controls 282 34 237 188 99 134 48 146.!:_ 94 BW (1273±57g), GA (29.3±0.4 wks), or severity of RDS during the All of the infants with PFC, except one, had TxB2 levels >300pg/ first 48 h, as compared between the INO and the GLU groups.
    [Show full text]
  • Palliative Care in Critical Perinatal and Neonatal Cardiac Patients
    children Review Redefining the Relationship: Palliative Care in Critical Perinatal and Neonatal Cardiac Patients Natasha S. Afonso 1, Margaret R. Ninemire 1, Sharada H. Gowda 2, Jaime L. Jump 1,3, Regina L. Lantin-Hermoso 4, Karen E. Johnson 2, Kriti Puri 1, Kyle D. Hope 4, Erin Kritz 1, Barbara-Jo Achuff 1, Lindsey Gurganious 3 and Priya N. Bhat 1,* 1 Sections of Critical Care Medicine and Cardiology, Department of Pediatrics, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX 77030, USA; [email protected] (N.S.A.); [email protected] (M.R.N.); [email protected] (J.L.J.); [email protected] (K.P.); [email protected] (E.K.); [email protected] (B.-J.A.) 2 Section of Neonatology, Department of Pediatrics, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX 77030, USA; [email protected] (S.H.G.); [email protected] (K.E.J.) 3 Section of Palliative Care Medicine, Department of Pediatrics, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX 77030, USA; [email protected] 4 Section of Cardiology, Department of Pediatrics, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX 77030, USA; [email protected] (R.L.L.-H.); [email protected] (K.D.H.) * Correspondence: [email protected]; Tel.: +1-832-826-6230; Fax: +1-832-825-4252 Abstract: Patients with perinatal and neonatal congenital heart disease (CHD) represent a unique population with higher morbidity and mortality compared to other neonatal patient groups. Despite Citation: Afonso, N.S.; Ninemire, an overall improvement in long-term survival, they often require chronic care of complex medical M.R.; Gowda, S.H.; Jump, J.L.; illnesses after hospital discharge, placing a high burden of responsibility on their families.
    [Show full text]
  • Moving Neonatology Into the Modern Era of Drug Development
    Moving Neonatology into the Modern Era of Drug Development: Overview of Potential consortium projects and deliverables Mark Turner – University of Liverpool Ron Portman - Novartis Pharmaceuticals Wolfgang Göpel - The German Neonatal Network Stephen Spielberg – Consultant Moving Neonatology into the Modern Era of Drug Development: a clinical perspective Mark Turner Declarations of interest Chair, European Network for Paediatric Research at the European Medicines Agency Publically-funded European Commission FP7, NIHR, BLISS, MRC, AMR • Associate Director (International Liaison) National Institute for Health Research, Children’s Theme • Scientific Coordinator Global Research in Paediatrics (GRiP) Commercial: Pecuniary, non-personal Consultancies Product-specific / National PI: Chiesi, Shire, Non-product-specific: Janssen 3 A clinician’s view of the future Vision Differences from the present Implications for practice 4 Clinical Vision Improved outcomes due to new medicines that come to market rapidly This happens because of: Intelligent pipelines for drug development Smart trials Optimise use of existing data Minimise the impact on babies and families Feasible studies High quality data Line listings, source data verification (SDV) Networks 5 Different approach to most academic neonatal research Regulatory studies canNOT rely on Cochrane Reviews May need to recognise need for different approaches for Pragmatic trials different purposes HTA etc. Examples of differences Need for well-qualified standard of care Justifiable
    [Show full text]
  • World Neonatology, Pediatrics and Developmental Medicine Conference
    2019 Conference Announcement 2020 Journal of Emergency and Internal Medicine Vol.3 No.2 World Neonatology, Pediatrics and Developmental Medicine Conference Leonardo Milella Paediatric Hospital Giovanni XXIII, Italy, E-mail: [email protected] Neonatology deals with the study of medical care of Neonatology Meetings 2020 is being organized to Newborn Infants, especially the ill or premature broaden the scope of the research in the field of newborn. It includes medical diagnosis, treatment & neonatology, perinatology, neonatal intensive care unit prevention of diseases. (NICU), neonatal hepatitis, neonatal genetics, pediatric Conference Series LLC Ltd. is pleased to welcome you to our & neonatal nursing, neonatal CNS disorders, pediatrics World Neonatology, Pediatrics and Developmental Medicine nutrition & metabolism, neonatal & pediatric cardiology, Conference, which is to be held on September 07-08, 2020 at neonatal nutrition & maternal factors, neonatal Prague, Czech Republic. Neonatology Meeting 2020 will be an rheumatology, vaccination & immunization, neonatology inspired and strengthening worldwide gathering reflecting the research, pediatric gastroenterology, pediatric course of Pediatrics in the 21st century in a protected yet endocrinology, maternal & child care, congenital energizing state that offers an extensive variability of malformations & birth complications, and neonatal preoccupations to members of all foundations. This assembly diseases. gives a wonderful chance to talk about the most recent Target Audience: Neonatologists;
    [Show full text]
  • Neonatal ICU APPE Student Rotation
    Neonatal Intensive Care Unit APPE Student Rotation Developed by the Section of Inpatient Care Practitioners Section Advisory Group on Pharmacy Practice Experiences (PPE) Rotation Description The Neonatal Intensive Care Unit (ICU) rotation will help students become familiar with the key skills required as a clinical pharmacist in the Neonatal Intensive Care Unit (NICU). It will provide the student with the opportunity to be exposed and participate in the essential roles of the pharmacist in the NICU; including optimization of medication use through interaction with the Neonatal ICU Teams; order review; drug therapy monitoring; participation in high‐risk procedures including resuscitation and other time dependent emergencies; monitoring use of high‐risk medications; medication procurement and preparation; and provision of drug information. The goal of this rotation is to provide a clinical pharmacy practice environment for students to become familiar with the role of the pharmacist in the NICU, obtain experience in working with an interdisciplinary team and to work to optimize pharmacotherapeutic management and improve patient care and safety through helping to provide the services listed above. The student will participate in several activities to improve the student’s working knowledge and experience with NICU patients – which include a wide scope of severity from step‐down to the critically ill. Goals and Objectives The preceptor and student should agree on which goals and objectives are appropriate for the rotation based on rotation site, rotation objectives delineated by School/College of Pharmacy, rotation length, and student interests. The following are a list of potential goals and objectives: 1. Outline the workflow and pharmacy operations in the Neonatal Intensive Care Unit, as well as outline patient path from Labor and Delivery setting to hospital admission in Neonatal Intensive Care Unit.
    [Show full text]
  • Beneficial Effects of Surgical Closure of Atrial Septal Defect Outweigh Potential Complications in Sick Infants
    https://www.scientificarchives.com/journal/journal-of-clinical-cardiology Journal of Clinical Cardiology Commentary Beneficial Effects of Surgical Closure of Atrial Septal Defect Outweigh Potential Complications in Sick Infants Takeshi Tsuda1,2*, Abdul M. Bhat1,2 1Nemours Cardiac Center, Alfred I. duPont Hospital for Children, Nemours Children’s Health System, 1600 Rockland Road, Wilmington, DE 19803, USA 2Department of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, 11th and Walnut, Philadelphia, PA 19107, USA *Correspondence should be addressed to Takeshi Tsuda; [email protected] Received date: February 10, 2021, Accepted date: May 18, 2021 Copyright: © 2021 Tsuda T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Infants and children with isolated atrial septal defect (ASD) usually do not develop clinical signs or symptoms. However, infants with premature birth complicated by chronic lung disease may develop certain problems including respiratory distress, dependency upon supplemental oxygen and/or mechanical ventilation, failure to thrive, and prolonged hospitalization; these are induced largely by excessive pulmonary blood flow through ASD. Although transcatheter approach is less invasive than surgery, its feasibility is often limited by anatomical conditions of ASD and the size of the patients. In these circumstances, surgical closure can be performed safely and effectively even in sick infants to improve clinical status. When transcatheter approach is not feasible, the surgical closure of ASD results in a favorable outcome by eliminating excessive pulmonary blood flow, mitigating the need of positive pressure ventilation more quickly, and promoting better physical growth.
    [Show full text]
  • Young Children with Atrial Septal Defect
    Young children with atrial septal defect Gustaf Tanghöj Department of Clinical Sciences, Paediatrics Umeå 2020 i Responsible publisher under Swedish law: The Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) Dissertation for PhD: [email protected] ISBN: 978-91-7855-280-1 (print) ISBN: 978-91-7855-281-8 (pdf) ISSN: 0346-6612 Cover design sketched by Gustaf Tanghöj Electronic version available at: http://umu.diva-portal.org/ Printed by: Tryckservice / Print Service, Umeå University Umeå, Sweden 2020 ii “Do or do not, there is no try.” /Yoda iii iv Contents Contents v List of papers vii Abbreviations viii Definitions ix Abstract x Sammanfattning på svenska xii Introduction 1 Secundum atrial septal defect (ASD II) pathophysiology and natural history 1 ASD II indications for closure and state of the art 3 ASD II closure, risk assessment, and adverse events 4 ASD II closure in children and risk of adverse events by weight and age 5 Preterm birth and CHD 7 The preterm child’s circulation, pathophysiology and cardiac morphology 8 Preterm children with bronchopulmonary dysplasia and pulmonary hypertension 10 ASD II with bronchopulmonary dysplasia and pulmonary hypertension 11 Registries 12 Epidemiological methods 12 Key factors in introduction 15 Aim of the thesis 16 Materials and methods 17 Study design and materials, Paper I 19 Study design and materials, Papers II–III 22 Study design and materials, Paper IV 24 Ethics 25 Results 26 Paper I. Early complications after percutaneous closure of atrial septal defect in infants with procedural weight less than 15 kg 26 Paper II.
    [Show full text]
  • Week 4: Neonatology
    Week 4: Neonatology Cardiology: Neonatal Cardiology Tuesday, July 21 4:30-6:00 pm EDT Moderators Heike Rabe Ayan Rajgarhia EDT Abstract Title Presenting Author 4:30 pm Introduction & General Information Assessment of Myocardial Function in Neonates Conceived by 4:35 pm 3374931 Assisted Reproductive Technologies Using Deformation Imaging Aisling Smith Low Birth Weight Neonates Undergoing Cardiac Surgery: Have 4:45 pm 3379499 Outcomes Improved Over Time? Minso Kim Delayed fetal brain growth is associated with impaired motor and 4:55 pm 3382642 language development in infants with congenital heart disease Kushal Kapse Protective role of CXCR7 agonism in experimental model of neonatal hyperoxia induced cardiac dysfunction in former preterm 5:05 pm 3378444 survivors Merline Benny Cardiac dysfunction in hypoxic ischemic encephalopathy is 5:15 pm 3369842 associated with increase rate of death and brain injury by MRI Gabriel Altit Prenatally diagnosed coronary artery fistulae are associated with 5:25 pm 3379329 lethal aneuploidies and coronary artery stenosis Andrea Pisesky Percutaneous closure of Patent Ductus Arteriosus in Very Low Weight (≤1.5kg) and Low Weight (≤6kg) Infants: A Systematic 5:35 pm 3378984 Review and Meta-Analysis Adrianne Bischoff Impact of Neonatal Management Strategy on Feeding and Somatic Growth in Infants with Symptomatic Tetralogy of Fallot: Results from the Congenital Catheterization Research 5:45 pm 3378038 Collaborative George Nicholson 5:55 pm Wrap Up Note: Schedule subject to change based on presenter availability. < Return to Abstract Search Print CONTROL ID: 3374931 TITLE: Assessment of Myocardial Function in Neonates Conceived by Assisted Reproductive Technologies Using Deformation Imaging PRESENTER: Aisling Smith AUTHORS (LAST NAME, FIRST NAME): Smith, Aisling1; Franklin, Orla2; Mocanu, Edgar V.1; McCallion, Naomi1; EL-Khuffash, Afif F.1 AUTHORS/INSTITUTIONS: A.
    [Show full text]